Moderna’s COVID-19 Vaccine Spurs Immune Response In All Phase I Subjects At All Doses
Executive Summary
Neutralizing antibodies were seen in all 45 people injected across three dose levels in the first-in-human study. The middle dose of 100mcg will be tested in the company’s Phase III trial starting 27 July.
You may also be interested in...
BIO Calls For Journal Publication Of COVID-19 Trial Data, Independent FDA
In an open letter to the biopharmaceutical industry, BIO lays out principles for conducting COVID-19 clinical trials and disclosing and using the data. Senator Durbin asks eight vaccine makers backed by Operation Warp Speed how they will withstand political pressure to speed up the approval process.
Moderna Sets High Coronavirus Vaccine Pricing Bar In Small, Early Deals
Company has executed $400m worth of deals with smaller governments reflecting a $32-$37 price per dose for the two-shot mRNA-1273 vaccine, but said larger deals will be done at lower prices.
Moderna Sets High Coronavirus Vaccine Pricing Bar In Small, Early Deals
The company has executed $400m worth of deals with smaller governments reflecting a $32-$37 price per dose for the two-shot mRNA-1273 vaccine, but said larger deals will be done at lower prices.